GlassScriptPhysician profile
Steven Urbaniak
NPI 1891774634
$22,368.43
in general payments reported to CMS, 2019-2025
60 companies · $3,761 in 2025
The $3,761 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,326 · 2020: $1,900 · 2021: $3,701 · 2022: $3,853 · 2023: $3,529 · 2024: $3,298 · 2025: $3,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $150 · Education: $13.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,425.27 |
| Consulting Fee | $150.00 |
| Education | $13.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,073.61 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Biogen, INC. | $1,496.79 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,433.93 | 2019-2025 | |
| Upsher-Smith Laboratories LLC | $1,396.99 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $1,165.77 | 2020-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $1,144.39 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $1,087.25 | 2019-2025 | Briviact |
| Teva Pharmaceuticals USA, INC. | $1,054.20 | 2019-2025 | Ajovy, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $968.97 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $947.89 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Sk Life Science, INC. | $697.65 | 2020-2025 | Xcopri |
| Impel Pharmaceuticals INC. | $624.26 | 2022-2023 | Trudhesa |
| E.R. Squibb & Sons, L.L.C. | $615.78 | 2020-2025 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $495.40 | 2020-2021 | |
| Pfizer INC. | $486.74 | 2023-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Urbaniak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.